# Perioperative FOLFIRINOX for Patients With Resectable Pancreatic Adenocarcinoma: A Pilot Study

> **NCT02782182** · PHASE1 · TERMINATED · sponsor: **University of Chicago** · enrollment: 1 (actual)

## Conditions studied

- Pancreatic Ductal Adenocarcinoma (PDAC)

## Interventions

- **DRUG:** FOLFIRINOX (oxaliplatin, leucovorin, irinotecan)

## Key facts

- **NCT ID:** NCT02782182
- **Lead sponsor:** University of Chicago
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2016-06-28
- **Primary completion:** 2018-03-29
- **Final completion:** 2018-03-29
- **Target enrollment:** 1 (ACTUAL)
- **Why stopped:** Closed early due to poor accrual.
- **Last updated:** 2019-03-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02782182

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02782182, "Perioperative FOLFIRINOX for Patients With Resectable Pancreatic Adenocarcinoma: A Pilot Study". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT02782182. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*